This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by You, X.-F.
Right arrow Articles by Jiang, J.-D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by You, X.-F.
Right arrow Articles by Jiang, J.-D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2009, p. 4525-4528, Vol. 53, No. 10
0066-4804/09/$08.00+0     doi:10.1128/AAC.00223-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

In Vivo Antibacterial Activity of Vertilmicin, a New Aminoglycoside Antibiotic{triangledown}

Xue-Fu You,{dagger}* Cong-Ran Li,{dagger} Xin-Yi Yang, Min Yuan, Wei-Xin Zhang, Ren-Hui Lou, Yue-Ming Wang, Guo-Qing Li, Hui-Zhen Chen, Dan-Qing Song, Cheng-Hang Sun, Shan Cen, Li-Yan Yu, Li-Xun Zhao, and Jian-Dong Jiang*

Laboratory of Pharmacology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Received 18 February 2009/ Returned for modification 4 May 2009/ Accepted 15 July 2009

Vertilmicin is a novel aminoglycoside antibiotic with potent activity against gram-negative and -positive bacteria in vitro. In this study, we further evaluated the efficacy of vertilmicin in vivo in systemic and local infection animal models. We demonstrated that vertilmicin had relatively high and broad-spectrum activities against mouse systemic infections caused by Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Enterococcus faecalis. The 50% effective doses of subcutaneously administered vertilmicin were 0.63 to 0.82 mg/kg, 0.18 to 0.29 mg/kg, 0.25 to 0.99 mg/kg, and 4.35 to 7.11 mg/kg against E. coli, K. pneumoniae, S. aureus, and E. faecalis infections, respectively. The therapeutic efficacy of vertilmicin was generally similar to that of netimicin, better than that of gentamicin in all the isolates tested, and better than that of verdamicin against E. coli 9612 and E. faecalis HH22 infections. The therapeutic efficacy of vertilmicin was further confirmed in local infection models of rabbit skin burn infection and mouse ascending urinary tract infection.

* Corresponding author. Mailing address for Xue-Fu You: Laboratory of Pharmacology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Phone: 86-10-63165290. Fax: 86-10-63017302. E-mail: xuefuyou{at}hotmail.com. Mailing address for Jian-Dong Jiang: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Phone: 86-10-63165290. Fax: 86-10-63017302. E-mail: jiang.jdong{at}163.com

{triangledown} Published ahead of print on 27 July 2009.

{dagger} X.-F.Y. and C.-R.L. contributed equally to this work.

Antimicrobial Agents and Chemotherapy, October 2009, p. 4525-4528, Vol. 53, No. 10
0066-4804/09/$08.00+0     doi:10.1128/AAC.00223-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»